<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022838</url>
  </required_header>
  <id_info>
    <org_study_id>2015/1729REK</org_study_id>
    <nct_id>NCT03022838</nct_id>
  </id_info>
  <brief_title>The Effects of Caffeine Withdrawal on Migraine</brief_title>
  <official_title>The Effects of Caffeine Withdrawal on Migraine - a Randomized, Double-blind, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordlandssykehuset HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sporadic and chronic dietary consumption of caffeine has substantial biological effects on
      the nervous system. The effects on migraine are at large not known. In this study we want to
      assess the effects of caffeine withdrawal on migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The actions of caffeine as an antagonist of adenosine receptors have been extensively
      studied, and there is no doubt that both daily and sporadic dietary consumption of caffeine
      has substantial biological effects on the nervous system. The current opinion is that
      caffeine both can cure and trigger headaches. Caffeine is a component of many combination
      drugs marketed for the relief of headaches, but on the other hand it is strongly incriminated
      as a risk factor for developing chronic headache. Withdrawal may cause symptom constellations
      similar to the migraine syndrome. Further, caffeine consumption may affect sleep and
      alertness, possibly influencing the risk of migraine attacks. .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine days</measure>
    <time_frame>10 weeks</time_frame>
    <description>Reduction from baseline in monthly migraine days (withdrawal vs. caffeine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Withdrawal symptoms and/or syndrome (according to criteria)</measure>
    <time_frame>2 first days after caffeine withdrawal(withdrawal vs. caffeine)</time_frame>
    <description>If patients report withdrawal symptoms, these will be recorded and eventually diagnosed as either caffeine withdrawal symptoms or migraineous symptoms in accordance with international criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine attacks</measure>
    <time_frame>10 weeks</time_frame>
    <description>Reduction from baseline in monthly migraine attacks (withdrawal vs. caffeine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep improvement</measure>
    <time_frame>10 weeks</time_frame>
    <description>Reduction from baseline in PSQI and measured by actigraphy (withdrawal vs. caffeine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>10 weeks</time_frame>
    <description>Reduction from baseline in HIT-6 (withdrawal vs. caffeine)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Migraine</condition>
  <condition>Caffeine Withdrawal</condition>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caffeine tablets (Recip) 100 mg, 300-800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).</description>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Recip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  migraine present for at least 1 year and fulfilling diagnostic criteria (ICHD-3 beta)

          -  =/&gt; 3 migraine attacks per month

          -  no migraine prophylaxis the last month

          -  consumption =/&gt; 300 mg and &lt;/= 800 mg caffeine per day the last month

          -  signed consent

        Exclusion Criteria:

          -  suspicion of medication-overuse headache

          -  pregnancy and breast feeding

          -  serious co-morbidity or conditions requiring Medical treatment or caution

          -  working night shift

          -  use of drugs with moderate or major interactions with caffeine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan T Henriksen</last_name>
    <role>Study Director</role>
    <affiliation>Department for research and patient safety, Nordland Hospital trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karl B Alstadhaug, MD, PhD</last_name>
    <phone>7553400</phone>
    <email>karl.bjornar.alstadhaug@nlsh.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilde K Ofte, MD, PhD</last_name>
    <phone>7553400</phone>
    <email>hilde.karen.ofte@nlsh.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <zip>8011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl B Alstadhaug, MD, PhD</last_name>
      <phone>75534000</phone>
      <email>karl.bjornar.alstadhaug@nlsh.no</email>
    </contact>
    <contact_backup>
      <last_name>Hilde K Ofte, MD, PhD</last_name>
      <phone>75534000</phone>
      <email>hilde.karen.ofte@nlsh.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, NLSH HF</name>
      <address>
        <city>Bodø</city>
        <zip>8092</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Alstadhaug, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Karl Alstadhaug, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology</name>
      <address>
        <city>Tromsø</city>
        <zip>9037</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai I Müller, PhD</last_name>
      <phone>+ 47 776 26000</phone>
      <email>kai.ivar.muller@unn.no</email>
    </contact>
    <investigator>
      <last_name>Kai I Muller, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

